Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312606 | 0.81 | PDE4B (0.51) | CNR2 | |
| SCHEMBL5749019 | 0.79 | PTGER4 (0.44) | CYP1A2CYP2C9CYP2C19PTGER4 | |
| SCHEMBL5778513 | 0.79 | PTGER4 (0.43) | PTGER4 | |
| SCHEMBL5840163 | 0.78 | CNR1 (0.44) | — | |
| SCHEMBL5839215 | 0.78 | CNR1 (0.44) | — | |
| SCHEMBL5750409 | 0.77 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5750463 | 0.76 | PTGER4 (0.44) | CNR2PTGER4 | |
| SCHEMBL5839702 | 0.75 | PDE4B (0.50) | CYP3A4 | |
| SCHEMBL5839698 | 0.75 | PDE4B (0.50) | CYP3A4 | |
| SCHEMBL5779293 | 0.73 | PDE4B (0.49) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1651609-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | P2RX7 832/4885CYP1A2 555/4885CYP3A4 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.